- Home
- SHW vs GRDN Comparison
SHW vs GRDN Comparison
Compare SHW & GRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHW
- GRDN
- Stock Information
- Founded
- SHW 1866
- GRDN 2004
- Country
- SHW United States
- GRDN United States
- Employees
- SHW N/A
- GRDN N/A
- Industry
- SHW RETAIL: Building Materials
- GRDN Retail-Drug Stores and Proprietary Stores
- Sector
- SHW Consumer Discretionary
- GRDN Consumer Staples
- Exchange
- SHW Nasdaq
- GRDN Nasdaq
- Market Cap
- SHW 88.6B
- GRDN 1.6B
- IPO Year
- SHW N/A
- GRDN 2024
- Fundamental
- Price
- SHW $363.47
- GRDN $26.50
- Analyst Decision
- SHW Buy
- GRDN Strong Buy
- Analyst Count
- SHW 15
- GRDN 2
- Target Price
- SHW $395.57
- GRDN $23.00
- AVG Volume (30 Days)
- SHW 1.4M
- GRDN 90.1K
- Earning Date
- SHW 04-29-2025
- GRDN 05-12-2025
- Dividend Yield
- SHW 0.87%
- GRDN N/A
- EPS Growth
- SHW 12.81
- GRDN N/A
- EPS
- SHW 10.59
- GRDN N/A
- Revenue
- SHW $23,036,900,000.00
- GRDN $1,282,307,000.00
- Revenue This Year
- SHW $2.60
- GRDN $11.36
- Revenue Next Year
- SHW $4.71
- GRDN $2.63
- P/E Ratio
- SHW $34.28
- GRDN N/A
- Revenue Growth
- SHW 0.26
- GRDN 19.55
- 52 Week Low
- SHW $282.09
- GRDN $14.16
- 52 Week High
- SHW $400.42
- GRDN $26.91
- Technical
- Relative Strength Index (RSI)
- SHW 62.03
- GRDN N/A
- Support Level
- SHW $350.81
- GRDN N/A
- Resistance Level
- SHW $363.43
- GRDN N/A
- Average True Range (ATR)
- SHW 6.43
- GRDN 0.00
- MACD
- SHW 1.32
- GRDN 0.00
- Stochastic Oscillator
- SHW 91.97
- GRDN 0.00
About SHW Sherwin-Williams Company (The)
Sherwin-Williams is the largest provider of architectural paint in the United States. The company has over 5,000 stores and sells premium paint at higher price points than most competitors. Sherwin-Williams also sells paint-related products in big-box stores and provides coatings for original equipment manufacturers.
About GRDN Guardian Pharmacy Services Inc. Class A Common Stock
Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.